PamelaRDrullinskyMD

Physician

Overview of Dr. Drullinsky

Dr. Pamela Drullinsky is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from Tel Aviv University Sackler and has been in practice 26 years. She is one of 495 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She also speaks multiple languages, including Spanish. She has more than 30 publications and over 500 citings.

Office
1919 Madison Avenue
(Entrance on 124th Street)
New York, NY 10035
Book by Phone+1(251) 581-9562

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
Tel Aviv University SacklerClass of 1991

Certifications & Licensure

FL State Medical License 2022 - Present
NJ State Medical License 1997 - 2025
NY State Medical License 1992 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer Start of enrollment: 2008 Jan 01
Completed
Not Applicable

Publications & Presentations

PubMed

151 citations
Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer.
Monika Engelhardt, Pamela Drullinsky, Jose G. Guillem, Malcolm A.S. Moore
Clinical Cancer Research. 1997-11-01
85 citations
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.
Komal Jhaveri, Sarat Chandarlapaty, Diana Lake, Teresa Gilewski, Mark E. Robson
Clinical Breast Cancer. 2014-06-01
91 citations
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER ...
Susan Dent, J. Cortes, Yunjoo Im, Véronique Diéras, Nadia Harbeck
Annals of Oncology. 2021-02-01

Abstracts/Posters

A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
Pamela Drullinsky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Pamela Drullinsky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Other Languages

Spanish